ReachMD julkinen
[search 0]
Lisää
Download the App!
show episodes
 
Artwork
 
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
  continue reading
 
Loading …
show series
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/resolving-practice-barriers-to-consolidative-immunotherapy-in-stage-iii-nsclc/24386/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectabili…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consolidation-immunotherapy-after-concurrent-crt-what-do-real-world-data-show/24387/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectabili…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consolidative-immunotherapy-following-scrt-vs-rt-only-in-stage-iii-nsclc/24388/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, a…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/chemoradiotherapy-toxicities-how-do-they-impact-starting-immunotherapy/24389/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, app…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consolidative-immunotherapy-in-unresectable-stage-iii-nsclc-with-oncogenic-drivers/24391/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resect…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/immunotherapy-approaches-in-unresectable-stage-iii-nsclc-whats-on-the-horizon/24390/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectabili…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/accurate-staging-and-determining-resectability-in-nsclc/24385/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical …
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-consolidative-immunotherapy-in-unresectable-stage-iii-nsclc-case-discussion/24392/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining re…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/differentiating-and-managing-pneumonitis-in-unresectable-stage-iii-nsclc-case-discussion/24393/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining …
  continue reading
 
CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/initial-btk-inhibitor-based-treatment-selection-in-a-treatment-naive-symptomatic-unfit-older-patient-with-comorbidities-and-high-risk-cytogenetics/24452/ Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizi…
  continue reading
 
CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/selection-of-btk-inhibitor-following-frontline-chemoimmunotherapy-in-older-patients-with-comorbidities/24453/ Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-g…
  continue reading
 
CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-changing-covalent-btk-inhibitor-treatment-in-a-patient-intolerant-to-ibrutinib-or-acalabrutinib/24454/ Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences betwe…
  continue reading
 
CME credits: 0.25 Valid until: 09-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/attr-cm-management-pearls-from-recent-clinical-trials-and-tailoring-therapy/18005/ Struggling to manage ATTR-CM? Our faculty are exploring the key considerations shaping current clinical trial design and how innovations might change our approach to t…
  continue reading
 
CME credits: 0.50 Valid until: 09-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimal-sequencing-of-adcs-in-endocrine-refractory-hrher2-metastatic-breast-cancer/18104/ The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast ca…
  continue reading
 
CME credits: 1.00 Valid until: 06-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/are-two-pathways-better-than-one-experts-discuss-the-role-of-ang2-vegfa-inhibition-in-retinal-vascular-disease/16620/ Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of re…
  continue reading
 
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/current-and-emerging-biomarkers-of-response-to-immunotherapeutic-regimens/24356/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell car…
  continue reading
 
CME credits: 1.00 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/evolutions-in-duchenne-muscular-dystrophy-treatment-implications-for-the-present-and-future/20369/ There are ongoing clinical trials and approvals for new genetic and non-genetic therapies for Duchenne muscular dystrophy. Determining the most suitabl…
  continue reading
 
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-with-immunotherapies/24358/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They d…
  continue reading
 
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-immunotherapy-in-the-treatment-of-recurrent-or-metastatic-hnscc-the-evidence/24355/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck sq…
  continue reading
 
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/24357/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic …
  continue reading
 
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/24359/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic …
  continue reading
 
CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/integration-is-the-key-to-success-how-will-the-new-scz-therapies-fit-into-clinical-treatment-paradigms/20299/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Har…
  continue reading
 
CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/not-all-therapy-needs-to-be-swallowed-or-injected-the-future-of-digital-therapeutics-to-alleviate-the-negative-symptoms-of-schizophrenia/20300/ This series of bite-sized episodes will provide important information on cognitive impairment associated w…
  continue reading
 
CME credits: 0.50 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/acc-2024-the-pioneer-af-pci-trial/24404/ This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to up…
  continue reading
 
CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/challenges-of-integrating-cognitive-remediation-in-cias/20296/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysi…
  continue reading
 
CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/glycines-role-in-driving-the-cognitive-symptoms-of-cias/20292/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysi…
  continue reading
 
CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/cias-effects-on-patients-and-caregivers-what-is-the-personal-and-economic-burden-caused-by-cias/20293/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and…
  continue reading
 
CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/20297/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to…
  continue reading
 
CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/tools-of-the-trade-measurement-based-care-for-cias/20295/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology…
  continue reading
 
Loading …

Pikakäyttöopas